TALLAHASSEE, Fla. - A Florida appeals court panel on Oct. 27 reversed a $7 million Accutane inflammatory bowel disease (IBD) verdict, finding that the plaintiff had not proven failure to warn and causation and that his claim was barred by the learned intermediary doctrine (Hoffman-La Roche Inc., et al. v. Adam W. Mason, No. 1D08-2023, Fla. App., 1st Dist.). From Mealey's Emerging Drugs & Devices